Effects of aripiprazole and olanzapine on body weight and lipid metabolism in schizophrenia patients

Abstract

Objective To observe and explore the effect of aripiprazole(Ari) and olanzapine(Ola) on body weight and lipid metabolism in schizophrenia(SP) patients. Methods 96 patients with SP were randomly divided into two groups, 48 cases in the observation group and the control group.The control group was treated with Ola, while the observation group was treated with Ari.Before and 6 weeks after treatment, the height, body weight, blood glucose(FBG), insulin(INS), low-density lipoprotein(LDL), triglycerides(TG), total cholesterol(TC) levels in the two groups were detected, insulin resistance index(IRI) and BMI were calculated. Results The differences of body weight, BMI, FBG, INS, IRI, LDL, TG, TC before treatment between the two groups were not statistically significant(t=0.161, 0.564, 0.277, 0.078, 0.092, 0.124, 0.421, 0.245, all P>0.05). After 6 weeks treatment, FBG, INS, IRI in the observation group were (4.71±0.58)mmol/L, (21.85±12.36)μU/mL and (4.62±2.14), the differences were not statistically significant compared with before treatment(t=0.800, 0.571, 0.276, all P>0.05). Those in the control group were (5.14±0.56)mmol/L, (28.54±11.25)μU/mL and (6.23±3.82), which were significantly higher than those before treatment(t=4.898, 3.361, 2.628, all P 0.05), those in the control group were significantly higher than before treatment(t=2.601, 3.834, 5.773, 5.838, 4.375, all P<0.05), and were also significantly higher than those in the observation group(t=3.052, 3.265, 5.264, 5.496, 4.188, all P<0.05). Conclusion Ari treatment for SP has no significant effect on glucose and lipid metabolism and body weight in patients, and the effect of Ola treatment on patients' body weight and lipid metabolism is more significant. Key words: Schizophrenia; Aripiprazole; Olanzapine